Mandate

Vinge advises Tele2 against TeliaSonera in historic competition law case

December 02, 2011

In its judgment dated 2 December 2011, the Stockholm District Court ordered TeliaSonera to pay an administrative fine of SEK 144 million for abuse of its dominant position on the ADSL market. According to the Court, TeliaSonera’s margin squeeze caused long-term effects restricting competition. The case was also the subject of a preliminary ruling before the Court of Justice (17 February 2011) and is of major significance as a matter of principle and from a practical perspective and the administrative fine is the highest amount imposed hitherto in Sweden for abuse of a dominant position. Tele2 intervened in the proceedings supporting the Competition Authority’s case and was represented by partners Carl Wetter and Johan Karlsson and associate Karl Samuelsson. Vinge’s team is also representing Tele2 in its action for damages against TeliaSonera due to the margin squeezing conduct. These proceedings are currently pending and Tele2 is claiming damages of SEK 873 million plus interest from TeliaSonera. 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026